[1] |
Khan SA, Davidson BR, Goldin RD, et al. Guidelines for the diagnosis and treatment of cholangiocarcinoma: an update[J]. Gut, 2012, 61(12):1657-1669.
|
[2] |
Brindley PJ, Bachini M, Ilyas SI, et al. Cholangiocarcinoma[J]. Nat Rev Dis Primers, 2021, 7(1):65.
|
[3] |
Nagino M, Ebata T, Yokoyama Y, et al. Evolution of surgical treatment for perihilar cholangiocarcinoma: a single-center 34-year review of 574 consecutive resections[J]. Ann Surg, 2013, 258(1):129-140.
|
[4] |
Cho A, Yamamoto H, Kainuma O, et al. Laparoscopy in the management of hilar cholangiocarcinoma[J]. World J Gastroenterol, 2014, 20(41):15153-15157.
|
[5] |
Nickel F, Haney CM, Kowalewski KF, et al. Laparoscopic versus open pancreaticoduodenectomy: a systematic review and meta-analysis of randomized controlled trials[J]. Ann Surg, 2020, 271(1):54-66.
|
[6] |
Feng F, Cao X, Liu X, et al. Laparoscopic resection for Bismuth type Ⅲ andⅣ hilar cholangiocarcinoma: how to improve the radicality without direct palpation[J]. J Surg Oncol, 2019, 120(8):1379-1385.
|
[7] |
Dindo D, Demartines N, Clavien PA. Classification of surgical complications: a new proposal with evaluation in a cohort of 6 336 patients and results of a survey[J]. Ann Surg, 2004, 240(2):205-213.
|
[8] |
Olthof PB, Miyasaka M, Koerkamp BG, et al. A comparison of treatment and outcomes of perihilar cholangiocarcinoma between Eastern and Western centers[J]. HPB, 2019, 21(3):345-351.
|
[9] |
Valle JW, Borbath I, Khan SA, et al. Biliary cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up[J]. Ann Oncol, 2016, 27(suppl 5):v28-37.
|
[10] |
Morizane C, Okusaka T, Mizusawa J, et al. Combination gemcitabine plus S-1 versus gemcitabine plus cisplatin for advanced/recurrent biliary tract cancer: the FUGA-BT (JCOG1113) randomized phase Ⅲ clinical trial[J]. Ann Oncol, 2019, 30(12):1950-1958.
|
[11] |
Lamarca A, Palmer DH, Wasan HS, et al. Second-line FOLFOX chemotherapy versus active symptom control for advanced biliary tract cancer (ABC-06): a phase 3, open-label, randomised, controlled trial[J]. Lancet Oncol, 2021, 22(5):690-701.
|
[12] |
Xiang S, Lau WY, Chen XP. Hilar cholangiocarcinoma: controversies on the extent of surgical resection aiming at cure[J]. Int J Colorectal Dis, 2015, 30(2):159-171.
|
[13] |
Lee W, Han HS, Yoon YS, et al. Laparoscopic resection of hilar cholangiocarcinoma[J]. Ann Surg Treat Res, 2015, 89(4):228-232.
|
[14] |
梁后杰, 秦叔逵, 沈锋, 等. CSCO胆道系统肿瘤诊断治疗专家共识(2019年版)[J]. 临床肿瘤学杂志, 2019, 24(9):828-838.
|
[15] |
Weber SM, DeMatteo RP, Fong Y, et al. Staging laparoscopy in patients with extrahepatic biliary carcinoma. analysis of 100 patients[J]. Ann Surg, 2002, 235(3): 392-399.
|
[16] |
徐建, 熊永福, 黄徐建, 等. 腹腔镜肝门部胆管癌根治性切除近期疗效的多中心临床研究[J]. 中华外科杂志, 2020, 58(10):758-764.
|
[17] |
窦常伟, 刘杰, 张春旭, 等. 腹腔镜与开腹肝门部胆管癌根治术近期疗效的比较[J]. 中华肝胆外科杂志, 2021, 27(4):274-278.
|
[18] |
秦婷婷, 王敏, 秦仁义, 等. 腹腔镜肝门部胆管癌根治术的安全性和有效性研究[J]. 中华普通外科杂志, 2021, 36(10):750-755.
|
[19] |
Yao XI, Wang X, Speicher PJ, et al. Reporting and guidelines in propensity score analysis: a systematic review of cancer and cancer surgical studies[J]. J Natl Cancer Inst, 2017, 109(8):djw323.
|
[20] |
申航瑞, 葛佳辰, 穆森茂, 等. 腹腔镜与开腹肝门部胆管癌根治术的近期临床疗效对比[J]. 中华肝胆外科杂志, 2022, 28(2):103-107.
|
[21] |
刘学青, 冯峰, 王文斌, 等. 32例腹腔镜肝门部胆管癌根治术的临床研究[J]. 中华肝胆外科杂志, 2019, 25(3):200-206.
|
[22] |
Li J, Xiong Y, Yang G, et al. Complete laparoscopic radical resection of hilar cholangiocarcinoma: technical aspects and long-term results from a single center[J]. Wideochir Inne Tech Maloinwazyjne, 2021, 16(1):62-75.
|
[23] |
王春明, 谭洪坤, 陈锟灵, 等. 腹腔镜与开腹手术切除治疗肝门部胆管癌疗效与安全性的荟萃分析[J]. 中华肝胆外科杂志, 2022, 28(2):133-138.
|